<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Lixte Biotechnology Holdings, Inc. — News on 6ix</title>
<link>https://6ix.com/company/lixte-biotechnology-holdings-inc</link>
<description>Latest news and press releases for Lixte Biotechnology Holdings, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 14 May 2026 21:18:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/lixte-biotechnology-holdings-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835921a78dffbe2df102bc8.webp</url>
<title>Lixte Biotechnology Holdings, Inc.</title>
<link>https://6ix.com/company/lixte-biotechnology-holdings-inc</link>
</image>
<item>
<title>LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update</title>
<link>https://6ix.com/company/lixte-biotechnology-holdings-inc/news/lixte-biotechnology-files-first-quarter-2026-quarterly-report-on-form-10-q-provides-operational-progress-update</link>
<guid isPermaLink="true">https://6ix.com/company/lixte-biotechnology-holdings-inc/news/lixte-biotechnology-files-first-quarter-2026-quarterly-report-on-form-10-q-provides-operational-progress-update</guid>
<pubDate>Thu, 14 May 2026 21:18:00 GMT</pubDate>
<description>BOCA RATON, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has filed its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission (“SEC”) for the first quarter ended March 31, 2026. The report is available on the Company’s website, www.lixte.com, and on the SEC’s website, www.sec.gov. “We are ma</description>
</item>
<item>
<title>LIXTE Biotechnology Holdings (LIXT) Positions LB-100 as Novel Approach in Cancer Treatment Landscape</title>
<link>https://6ix.com/company/lixte-biotechnology-holdings-inc/news/lixte-biotechnology-holdings-lixt-positions-lb-100-as-novel-approach-in-cancer-treatment-landscape</link>
<guid isPermaLink="true">https://6ix.com/company/lixte-biotechnology-holdings-inc/news/lixte-biotechnology-holdings-lixt-positions-lb-100-as-novel-approach-in-cancer-treatment-landscape</guid>
<pubDate>Mon, 20 Apr 2026 19:00:00 GMT</pubDate>
<description>LOS ANGELES, CA - April 20, 2026 (NEWMEDIAWIRE) - Boca Raton, Florida-based LIXTE Biotechnology Holdings (NASDAQ: LIXT) spent 2025 expanding its presence across multiple segments of oncology innovation. "The company is best known for its clinical-sta...</description>
</item>
<item>
<title>LIXTE Biotechnology (LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference</title>
<link>https://6ix.com/company/lixte-biotechnology-holdings-inc/news/lixte-biotechnology-lixt-reports-interim-ovarian-cancer-trial-results-at-sgo-conference</link>
<guid isPermaLink="true">https://6ix.com/company/lixte-biotechnology-holdings-inc/news/lixte-biotechnology-lixt-reports-interim-ovarian-cancer-trial-results-at-sgo-conference</guid>
<pubDate>Mon, 13 Apr 2026 19:30:00 GMT</pubDate>
<description>LOS ANGELES, CA - April 13, 2026 (NEWMEDIAWIRE) - LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company advancing cancer treatments, announced preliminary results from a clinical trial evaluating its proprietary compoun...</description>
</item>
<item>
<title>Lixte Biotech Holdings (LIXT) Advances Precision Oncology Strategy With LB-100, Expands Clinical and Strategic Partnerships</title>
<link>https://6ix.com/company/lixte-biotechnology-holdings-inc/news/lixte-biotech-holdings-lixt-advances-precision-oncology-strategy-with-lb-100-expands-clinical-and-strategic-partnerships</link>
<guid isPermaLink="true">https://6ix.com/company/lixte-biotechnology-holdings-inc/news/lixte-biotech-holdings-lixt-advances-precision-oncology-strategy-with-lb-100-expands-clinical-and-strategic-partnerships</guid>
<pubDate>Fri, 10 Apr 2026 19:00:00 GMT</pubDate>
<description>LOS ANGELES, CA - April 10, 2026 (NEWMEDIAWIRE) - Lixte Biotechnology (NASDAQ: LIXT) is emerging as a differentiated player in the oncology ecosystem, advancing a precision-driven approach to cancer treatment which focuses on improving the effectiven...</description>
</item>
<item>
<title>LIXTE Biotechnology Holdings (LIXT) Files 2025 Form 10-K, Highlights Transformational Year</title>
<link>https://6ix.com/company/lixte-biotechnology-holdings-inc/news/lixte-biotechnology-holdings-lixt-files-2025-form-10-k-highlights-transformational-year</link>
<guid isPermaLink="true">https://6ix.com/company/lixte-biotechnology-holdings-inc/news/lixte-biotechnology-holdings-lixt-files-2025-form-10-k-highlights-transformational-year</guid>
<pubDate>Thu, 02 Apr 2026 18:30:00 GMT</pubDate>
<description>LOS ANGELES, CA - April 2, 2026 (NEWMEDIAWIRE) - LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced it has filed its Annual Report on Form 10-K for the year ended Dec. 31, 2025, outlining a year marked by leadership changes, clinical progress and ...</description>
</item>
<item>
<title>LIXTE Biotechnology (LIXT) Has the World's Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes</title>
<link>https://6ix.com/company/lixte-biotechnology-holdings-inc/news/lixte-biotechnology-lixt-has-the-worlds-only-clinical-stage-pp2a-inhibitor-poised-to-improve-cancer-treatment-outcomes</link>
<guid isPermaLink="true">https://6ix.com/company/lixte-biotechnology-holdings-inc/news/lixte-biotechnology-lixt-has-the-worlds-only-clinical-stage-pp2a-inhibitor-poised-to-improve-cancer-treatment-outcomes</guid>
<pubDate>Wed, 01 Apr 2026 18:30:00 GMT</pubDate>
<description>LOS ANGELES, CA - April 1, 2026 (NEWMEDIAWIRE) - LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is in the unique position of holding the world's only clinical-stage protein phosphatase 2A ("PP2A") inhibitor, cal...</description>
</item>
<item>
<title>LIXTE Biotechnology (LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials</title>
<link>https://6ix.com/company/lixte-biotechnology-holdings-inc/news/lixte-biotechnology-lixt-strengthens-oncology-pipeline-through-expanded-lb-100-clinical-trials</link>
<guid isPermaLink="true">https://6ix.com/company/lixte-biotechnology-holdings-inc/news/lixte-biotechnology-lixt-strengthens-oncology-pipeline-through-expanded-lb-100-clinical-trials</guid>
<pubDate>Tue, 31 Mar 2026 19:00:00 GMT</pubDate>
<description>LOS ANGELES, CA - March 31, 2026 (NEWMEDIAWIRE) - Ovarian clear cell carcinoma and metastatic colon cancer remain among the most challenging malignancies to treat, with limited effective therapies and poor patient outcomes driving the urgent need for...</description>
</item>
<item>
<title>LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year</title>
<link>https://6ix.com/company/lixte-biotechnology-holdings-inc/news/lixte-biotechnology-files-2025-annual-report-on-form-10k-provides-operational-highlights-of-transformative-year-2</link>
<guid isPermaLink="true">https://6ix.com/company/lixte-biotechnology-holdings-inc/news/lixte-biotechnology-files-2025-annual-report-on-form-10k-provides-operational-highlights-of-transformative-year-2</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>BOCA RATON, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage</description>
</item>
<item>
<title>Lixte Biotech (LIXT) Advances Precision Oncology With LB-100, Strengthens Position Through Liora Technologies Partnership</title>
<link>https://6ix.com/company/lixte-biotechnology-holdings-inc/news/lixte-biotech-lixt-advances-precision-oncology-with-lb-100-strengthens-position-through-liora-technologies-partnership</link>
<guid isPermaLink="true">https://6ix.com/company/lixte-biotechnology-holdings-inc/news/lixte-biotech-lixt-advances-precision-oncology-with-lb-100-strengthens-position-through-liora-technologies-partnership</guid>
<pubDate>Fri, 27 Mar 2026 19:30:00 GMT</pubDate>
<description>LOS ANGELES, CA - March 27, 2026 (NEWMEDIAWIRE) - Lixte Biotech Holdings (NASDAQ: LIXT) is advancing the frontiers of precision oncology, developing therapies that complement existing cancer treatments while integrating cutting-edge data solutions. T...</description>
</item>
<item>
<title>Landmark Proton Therapy Data Changes the Conversation; LIXTE Biotechnology (LIXT) Saw It Coming</title>
<link>https://6ix.com/company/lixte-biotechnology-holdings-inc/news/landmark-proton-therapy-data-changes-the-conversation-lixte-biotechnology-lixt-saw-it-coming</link>
<guid isPermaLink="true">https://6ix.com/company/lixte-biotechnology-holdings-inc/news/landmark-proton-therapy-data-changes-the-conversation-lixte-biotechnology-lixt-saw-it-coming</guid>
<pubDate>Wed, 25 Mar 2026 19:00:00 GMT</pubDate>
<description>LOS ANGELES, CA - March 25, 2026 (NEWMEDIAWIRE) - For decades, radiation oncology advanced incrementally, improving precision through software and delivery techniques while the underlying physics of photon radiation remained largely unchanged. The co...</description>
</item>
<item>
<title>LIXTE Biotechnology (LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology Landscape</title>
<link>https://6ix.com/company/lixte-biotechnology-holdings-inc/news/lixte-biotechnology-lixt-advances-pp2a-inhibition-strategy-in-evolving-oncology-landscape</link>
<guid isPermaLink="true">https://6ix.com/company/lixte-biotechnology-holdings-inc/news/lixte-biotechnology-lixt-advances-pp2a-inhibition-strategy-in-evolving-oncology-landscape</guid>
<pubDate>Mon, 23 Mar 2026 19:00:00 GMT</pubDate>
<description>LOS ANGELES, CA - March 23, 2026 (NEWMEDIAWIRE) - Experts working across oncology are exploring how different treatment approaches can work together to improve outcomes for cancer patients. One area drawing significant attention involves combining im...</description>
</item>
<item>
<title>LIXTE Biotechnology Holdings (LIXT) Adds Innovative LiGHT Therapy to Pipeline</title>
<link>https://6ix.com/company/lixte-biotechnology-holdings-inc/news/lixte-biotechnology-holdings-lixt-adds-innovative-light-therapy-to-pipeline</link>
<guid isPermaLink="true">https://6ix.com/company/lixte-biotechnology-holdings-inc/news/lixte-biotechnology-holdings-lixt-adds-innovative-light-therapy-to-pipeline</guid>
<pubDate>Tue, 10 Mar 2026 18:26:29 GMT</pubDate>
<description>LOS ANGELES, CA - March 10, 2026 (NEWMEDIAWIRE) - LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, recently acquired Liora Technologies, which is pioneering proton therapy systems for treating tumors in various ty...</description>
</item>
<item>
<title>LIXTE Biotechnology (LIXT) Advances Lead Compound in Tumor Immunogenicity Research</title>
<link>https://6ix.com/company/lixte-biotechnology-holdings-inc/news/lixte-biotechnology-lixt-advances-lead-compound-in-tumor-immunogenicity-research</link>
<guid isPermaLink="true">https://6ix.com/company/lixte-biotechnology-holdings-inc/news/lixte-biotechnology-lixt-advances-lead-compound-in-tumor-immunogenicity-research</guid>
<pubDate>Mon, 09 Mar 2026 19:00:00 GMT</pubDate>
<description>LOS ANGELES, CA - March 9, 2026 (NEWMEDIAWIRE) - Immunotherapy has transformed cancer treatment over the past decade, yet one of oncology's most persistent challenges remains: Many tumors simply do not respond. Even breakthrough approaches such as PD...</description>
</item>
<item>
<title>LIXTE Biotechnology (LIXT) Appoints Sidney Braun as CEO of Liora Technologies Europe Subsidiary</title>
<link>https://6ix.com/company/lixte-biotechnology-holdings-inc/news/lixte-biotechnology-lixt-appoints-sidney-braun-as-ceo-of-liora-technologies-europe-subsidiary</link>
<guid isPermaLink="true">https://6ix.com/company/lixte-biotechnology-holdings-inc/news/lixte-biotechnology-lixt-appoints-sidney-braun-as-ceo-of-liora-technologies-europe-subsidiary</guid>
<pubDate>Wed, 18 Feb 2026 20:00:00 GMT</pubDate>
<description>LOS ANGELES, CA - February 18, 2026 (NEWMEDIAWIRE) - LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical and med-tech company advancing cancer treatments, announced the appointment of Sidney Braun as Chief Executive Officer o...</description>
</item>
<item>
<title>LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. Subsidiary</title>
<link>https://6ix.com/company/lixte-biotechnology-holdings-inc/news/lixte-biotechnology-appoints-sidney-braun-as-ceo-of-its-liora-technologies-europe-ltd-subsidiary</link>
<guid isPermaLink="true">https://6ix.com/company/lixte-biotechnology-holdings-inc/news/lixte-biotechnology-appoints-sidney-braun-as-ceo-of-its-liora-technologies-europe-ltd-subsidiary</guid>
<pubDate>Wed, 18 Feb 2026 13:00:00 GMT</pubDate>
<description>BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has appointed Sidney Braun as Chief Executive Officer of the Company’s Liora Technologies Europe Ltd. subsidiary (“Liora”). A veteran of the healthcare industry, Braun brings to Liora more than two decades of operational and strategic advisory experience at</description>
</item>
<item>
<title>LIXTE Biotechnology (LIXT) Bringing First-in-Class Approach to Chemo and Immunotherapy</title>
<link>https://6ix.com/company/lixte-biotechnology-holdings-inc/news/lixte-biotechnology-lixt-bringing-first-in-class-approach-to-chemo-and-immunotherapy</link>
<guid isPermaLink="true">https://6ix.com/company/lixte-biotechnology-holdings-inc/news/lixte-biotechnology-lixt-bringing-first-in-class-approach-to-chemo-and-immunotherapy</guid>
<pubDate>Thu, 12 Feb 2026 20:00:00 GMT</pubDate>
<description>LOS ANGELES, CA - February 12, 2026 (NEWMEDIAWIRE) - LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is focused on enhancing established cancer therapies by targeting a fundamental biological pathway involved in ...</description>
</item>
<item>
<title>LIXTE Biotechnology (LIXT) Aligns Liora and LiGHT System With LB-100 to Push Frontier of Cancer Treatment</title>
<link>https://6ix.com/company/lixte-biotechnology-holdings-inc/news/lixte-biotechnology-lixt-aligns-liora-and-light-system-with-lb-100-to-push-frontier-of-cancer-treatment</link>
<guid isPermaLink="true">https://6ix.com/company/lixte-biotechnology-holdings-inc/news/lixte-biotechnology-lixt-aligns-liora-and-light-system-with-lb-100-to-push-frontier-of-cancer-treatment</guid>
<pubDate>Tue, 10 Feb 2026 20:00:00 GMT</pubDate>
<description>LOS ANGELES, CA - February 10, 2026 (NEWMEDIAWIRE) - LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, recently acquired Liora Technologies, a company that's pioneering proton therapy systems for treating tumors in...</description>
</item>
<item>
<title>LIXTE Biotechnology (LIXT) Positions LB-100 to Expand Effectiveness of Standard Cancer Treatment</title>
<link>https://6ix.com/company/lixte-biotechnology-holdings-inc/news/lixte-biotechnology-lixt-positions-lb-203000189</link>
<guid isPermaLink="true">https://6ix.com/company/lixte-biotechnology-holdings-inc/news/lixte-biotechnology-lixt-positions-lb-203000189</guid>
<pubDate>Mon, 09 Feb 2026 20:30:00 GMT</pubDate>
<description>LOS ANGELES, CA - February 9, 2026 (NEWMEDIAWIRE) - LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is leading efforts in addressing some of the pressing challenges in cancer treatment. "Instead of developing sta...</description>
</item>
<item>
<title>Improving the Odds: How LIXTE Biotechnology (LIXT) Is Working to Make Cancer Therapies More Effective</title>
<link>https://6ix.com/company/lixte-biotechnology-holdings-inc/news/improving-odds-lixte-biotechnology-lixt-193000473</link>
<guid isPermaLink="true">https://6ix.com/company/lixte-biotechnology-holdings-inc/news/improving-odds-lixte-biotechnology-lixt-193000473</guid>
<pubDate>Thu, 05 Feb 2026 19:30:00 GMT</pubDate>
<description>LOS ANGELES, CA - February 5, 2026 (NEWMEDIAWIRE) - Despite decades of progress in oncology, many cancers remain resistant to treatment, not because therapies are unavailable, but because tumor cells adapt. Immunotherapies and chemotherapies can prod...</description>
</item>
<item>
<title>LIXTE Biotechnology Holdings (LIXT) Advances a Novel Approach to Enhancing Cancer Therapy</title>
<link>https://6ix.com/company/lixte-biotechnology-holdings-inc/news/lixte-biotechnology-holdings-lixt-advances-a-novel-approach-to-enhancing-cancer-therapy</link>
<guid isPermaLink="true">https://6ix.com/company/lixte-biotechnology-holdings-inc/news/lixte-biotechnology-holdings-lixt-advances-a-novel-approach-to-enhancing-cancer-therapy</guid>
<pubDate>Fri, 23 Jan 2026 20:00:00 GMT</pubDate>
<description>LOS ANGELES, CA - January 23, 2026 (NEWMEDIAWIRE) - LIXTE Biotechnology (NASDAQ: LIXT) is a clinical-stage pharmaceutical company leading efforts in addressing some of the pressing challenges in cancer treatment. Instead of developing standalone canc...</description>
</item>
</channel>
</rss>